TransMedics Group, Inc. — FY2021 Form 10-K
Reporting period: Year ended December 31, 2021; this is an annual filing, not a standalone fourth-quarter report. TransMedics is a commercial-stage medical technology company whose Organ Care System (OCS) preserves donor organs using portable warm perfusion. Its business is driven primarily by recurring sales of single-use disposable sets.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net revenue | $30.3 million | $25.6 million |
| Gross profit / gross margin | $21.2 million / 70% | $16.6 million / 65% |
| Operating expenses | $60.6 million | $43.0 million |
| Operating loss | $39.4 million | $26.4 million |
| Net loss | $44.2 million | $28.7 million |
| Cash used in operating activities | $28.9 million | $30.3 million |
- Revenue increased 18%. Lung revenue rose to $10.7 million from $6.2 million, and Heart revenue rose to $17.7 million from $14.2 million. Liver revenue declined to $1.9 million from $5.2 million, principally following completion of clinical-trial enrollment.
- Gross margin improved five percentage points, reflecting higher sales volume and a greater mix of higher-margin disposable sets. SG&A rose $14.1 million, mainly from commercial and National OCS Program expansion, personnel and stock-based compensation. R&D and clinical-trial expense increased $3.5 million.
- At year-end, cash and cash equivalents were $25.6 million and marketable securities were $66.9 million, totaling $92.5 million. Current assets were $118.7 million and current liabilities $23.2 million.
- Long-term debt principal was $35.0 million, bearing a 9.5% rate at year-end and maturing in June 2023. The debt is secured by substantially all company and guarantor assets and includes a $3.0 million minimum-liquidity covenant; the company reported compliance at year-end.
- Investing activities provided $29.3 million, primarily from net sales and maturities of marketable securities; financing activities provided $1.4 million. The company reported that available cash, cash equivalents and marketable securities should fund operations and debt service for at least 12 months following the filing, while cautioning that assumptions could prove inaccurate.
Material changes, outlook and risks
- All three OCS products received FDA premarket approval by the end of Q3 2021. Heart approval covered DBD donor hearts; a supplement for DCD hearts was submitted in November 2021, with an FDA decision expected in 2022. Lung and Liver approvals include specified DBD and DCD indications.
- No numerical revenue or earnings guidance was provided. Management expects continued losses while expanding commercial operations and the National OCS Program, scaling manufacturing, and pursuing product development, clinical evidence and regulatory approvals.
- COVID-19 disrupted transplant procedures, customer budgets, staffing, travel, clinical enrollment and supply chains, and management said these effects could continue. Revenue remained below the company’s 2019 growth trajectory; the filing attributes this partly to the pandemic.
- Key risks include dependence on OCS adoption and reimbursement, a limited customer base (one customer represented 11% of 2021 revenue), single-source suppliers including Fresenius for Lung and Heart solutions, and reliance on a single manufacturing facility. International reimbursement remains a growth hurdle.
- European CE certificates were due to expire in September 2022, and the filing describes recertification under the EU Medical Device Regulation as necessary. Failure or delay could restrict sales in Europe. Other material exposures include debt refinancing at maturity, continued operating losses and potential need for additional capital.
- The company reported no material legal proceedings and no material weakness in internal control; management and the auditor concluded internal control over financial reporting was effective. The auditor identified revenue-recognition timing as a critical audit matter. The company adopted the new lease accounting standard in 2021, recording right-of-use assets and lease liabilities without a material effect on results or cash flow.
Investor verification priorities
- Track quarterly OCS procedure volumes, disposable-set sales and the durability of Lung and Heart growth, particularly given the Liver decline and customer concentration.
- Verify progress and timing on the Heart DCD supplement, post-approval studies and European MDR recertification.
- Monitor cash burn, available liquidity, funding needs and the plan to repay or refinance the $35.0 million debt due in June 2023.
- Assess whether National OCS Program expansion, supplier continuity and manufacturing capacity support growth without materially worsening costs or margins.
- Confirm that reimbursement remains available in the United States and improves in international markets; review whether COVID-related transplant and supply-chain disruptions persist.